The Indian pharmaceutical industry, known for its affordable and accessible medicines, faces increasing concerns about monopolies. A few dominant firms control a significant share of the market, potentially limiting competition and driving up prices for consumers. This issue raises worries about the long-term impact on patient access to affordable